TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07109726: A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Sponsor: Terremoto Biosciences Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 205 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT07109726 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07109726 Rescue Dossier →